Home/Pipeline/BPI-7711 (Rezivertinib)

BPI-7711 (Rezivertinib)

Non-Small Cell Lung Cancer (NSCLC)

Phase 3Active

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 3

Status

Active

Company

Beta Pharma

About Beta Pharma

Beta Pharma is a private, late-stage oncology biotech with a diversified pipeline of small molecule inhibitors targeting key oncogenic drivers like EGFR, CDK4/6, c-Met, KRAS, and FGFR. The company originated from a contract research organization (CRO) and leverages its synthetic chemistry expertise to develop novel therapeutics, with its lead asset, icotinib, already commercialized in China. Its business model is primarily therapeutic, focusing on both internal development and external partnerships to bring best-in-class oncology drugs to market. While likely pre-revenue in the US, it has a strategic history of partnering for development and commercialization in specific regions.

View full company profile

Therapeutic Areas

Oncology

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active